The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for vosoritide (BioMarin Pharmaceutical Australia Pty Ltd)
Active ingredients
vosoritide
Date of review outcome
Lapse date
Type
Priority review
Indication
Treatment of achondroplasia in patients less than 2 years of age whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing
Therapeutic area
Inherited bone disorder